Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

Bound­less Bio is trim­ming its on­col­o­gy pipeline in the wake of dis­ap­point­ing can­cer da­ta and switch­ing up its lead­er­ship just eight months af­ter de­but­ing on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER